VIPER
22 Dec 2020
Trial Summary
The primary purpose of this trial is to evaluate the safety and tolerability of Metformin (MET) in combination with sodium valproate (VPA) for the treatment of prostate cancer.
Acronym:
Viper
ACTRN/NCT /ethics:
ACTRN12616001021460
Scientific title:
Sodium Valporate/ Metformin combination therapy for prostate cancer (VIPER 1 trial)
Sponsor / Cooperative group:
Flinders University
Trial & Patient Characteristics
| Cancer Type | Prostate |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | Male |
| Tumour Stream | - |
| Cancer Stage | Early\In Situ; Locally Recurrent or Locally Advanced |
| Anticipated Start Date | 2016-12-01 |
| Anticipated End Date | - |
Participating Hospitals
| Hospital | Flinders Medical Centre |
|---|---|
| Clinical Trial Coordinator | Alex Scott-Hoy |
| alex.scott-hoy@sa.gov.au | |
| Phone | 08 8204 4830 |
| Principal Investigator | Dr Ganessan Kichenadasse |
| Recruitment Status | Recruiting |